JPWO2022224997A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022224997A5 JPWO2022224997A5 JP2023515503A JP2023515503A JPWO2022224997A5 JP WO2022224997 A5 JPWO2022224997 A5 JP WO2022224997A5 JP 2023515503 A JP2023515503 A JP 2023515503A JP 2023515503 A JP2023515503 A JP 2023515503A JP WO2022224997 A5 JPWO2022224997 A5 JP WO2022224997A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 185
- 150000001413 amino acids Chemical class 0.000 claims 166
- 239000002157 polynucleotide Substances 0.000 claims 77
- 102000040430 polynucleotide Human genes 0.000 claims 77
- 108091033319 polynucleotide Proteins 0.000 claims 77
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 11
- 210000004899 c-terminal region Anatomy 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 230000035772 mutation Effects 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004481 post-translational protein modification Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023169033A JP7822576B2 (ja) | 2021-04-22 | 2023-09-29 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021072429 | 2021-04-22 | ||
| JP2021072429 | 2021-04-22 | ||
| PCT/JP2022/018350 WO2022224997A1 (ja) | 2021-04-22 | 2022-04-21 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023169033A Division JP7822576B2 (ja) | 2021-04-22 | 2023-09-29 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022224997A1 JPWO2022224997A1 (https=) | 2022-10-27 |
| JPWO2022224997A5 true JPWO2022224997A5 (https=) | 2023-09-14 |
| JP7365654B2 JP7365654B2 (ja) | 2023-10-20 |
Family
ID=83722348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515503A Active JP7365654B2 (ja) | 2021-04-22 | 2022-04-21 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
| JP2023169033A Active JP7822576B2 (ja) | 2021-04-22 | 2023-09-29 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023169033A Active JP7822576B2 (ja) | 2021-04-22 | 2023-09-29 | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12227586B2 (https=) |
| EP (1) | EP4327823A4 (https=) |
| JP (2) | JP7365654B2 (https=) |
| KR (1) | KR20230171465A (https=) |
| CN (1) | CN117222672A (https=) |
| AR (1) | AR125398A1 (https=) |
| AU (1) | AU2022262542A1 (https=) |
| CA (1) | CA3217637A1 (https=) |
| CL (1) | CL2023003100A1 (https=) |
| CO (1) | CO2023015630A2 (https=) |
| CR (1) | CR20230490A (https=) |
| DO (2) | DOP2023000230A (https=) |
| EC (1) | ECSP23087918A (https=) |
| IL (1) | IL307744A (https=) |
| JO (1) | JOP20230261A1 (https=) |
| MX (1) | MX2023012432A (https=) |
| PE (1) | PE20241357A1 (https=) |
| SA (1) | SA523451235B1 (https=) |
| TW (1) | TW202309083A (https=) |
| WO (1) | WO2022224997A1 (https=) |
| ZA (1) | ZA202310292B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3256973A1 (en) * | 2022-05-12 | 2025-06-17 | Astellas Pharma Inc. | MULTI-SPECIFIC ANTI-CD3 AND ANTI-CD3 ANTIBODY |
| JP7730432B2 (ja) * | 2022-10-19 | 2025-08-27 | アステラス製薬株式会社 | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 |
| WO2026042803A1 (ja) * | 2024-08-21 | 2026-02-26 | アステラス製薬株式会社 | がん治療におけるプラチナ系薬剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| KR100999844B1 (ko) | 2006-07-19 | 2010-12-13 | 네오벌브 테크놀러지스 인크 | 고효율 방열 모듈을 구비한 고출력 ｌｅｄ 조명장치 |
| JPWO2008114733A1 (ja) | 2007-03-16 | 2010-07-01 | 協和発酵キリン株式会社 | 抗Ｃｌａｕｄｉｎ−４抗体 |
| AU2009298458B2 (en) | 2008-09-30 | 2015-10-08 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
| JP2014193853A (ja) * | 2013-03-01 | 2014-10-09 | Japan Health Sciences Foundation | 抗体、フラグメント、医薬組成物、分子及び腫瘍マーカー |
| AU2015244814B2 (en) * | 2014-04-07 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating antigen-binding molecule |
| JP6783797B2 (ja) | 2015-05-04 | 2020-11-11 | ピエリス ファーマシューティカルズ ゲーエムベーハー | 抗がん融合ポリペプチド |
| WO2019048040A1 (en) * | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
| US20210054076A1 (en) | 2018-01-05 | 2021-02-25 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
| AU2019235900B2 (en) * | 2018-03-14 | 2025-12-11 | Dana-Farber Cancer Institute, Inc. | Engineered cells, T cell immune modulating antibodies and methods for using the same |
| ES3044118T3 (en) * | 2018-07-12 | 2025-11-26 | Invox Pharma Ltd | Antibody molecules that bind cd137 and ox40 |
-
2022
- 2022-04-21 AU AU2022262542A patent/AU2022262542A1/en active Pending
- 2022-04-21 MX MX2023012432A patent/MX2023012432A/es unknown
- 2022-04-21 US US18/556,606 patent/US12227586B2/en active Active
- 2022-04-21 PE PE2023002906A patent/PE20241357A1/es unknown
- 2022-04-21 TW TW111115193A patent/TW202309083A/zh unknown
- 2022-04-21 KR KR1020237039211A patent/KR20230171465A/ko active Pending
- 2022-04-21 AR ARP220101032A patent/AR125398A1/es unknown
- 2022-04-21 IL IL307744A patent/IL307744A/en unknown
- 2022-04-21 EP EP22791768.9A patent/EP4327823A4/en active Pending
- 2022-04-21 CA CA3217637A patent/CA3217637A1/en active Pending
- 2022-04-21 WO PCT/JP2022/018350 patent/WO2022224997A1/ja not_active Ceased
- 2022-04-21 CR CR20230490A patent/CR20230490A/es unknown
- 2022-04-21 CN CN202280029125.XA patent/CN117222672A/zh active Pending
- 2022-04-21 JP JP2023515503A patent/JP7365654B2/ja active Active
-
2023
- 2023-09-29 JP JP2023169033A patent/JP7822576B2/ja active Active
- 2023-10-18 CL CL2023003100A patent/CL2023003100A1/es unknown
- 2023-10-19 JO JOJO/P/2023/0261A patent/JOP20230261A1/ar unknown
- 2023-10-19 DO DO2023000230A patent/DOP2023000230A/es unknown
- 2023-10-22 SA SA523451235A patent/SA523451235B1/ar unknown
- 2023-11-03 ZA ZA2023/10292A patent/ZA202310292B/en unknown
- 2023-11-20 CO CONC2023/0015630A patent/CO2023015630A2/es unknown
- 2023-11-21 EC ECSENADI202387918A patent/ECSP23087918A/es unknown
-
2025
- 2025-01-14 US US19/020,859 patent/US20250154272A1/en active Pending
- 2025-09-09 DO DO2025000223A patent/DOP2025000223A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7041516B2 (ja) | 共通軽鎖を有する二重特異性抗体又は抗体混合物 | |
| JP7773981B2 (ja) | 新型ポリペプチド複合物 | |
| CN108367075B (zh) | 4-1bb结合蛋白及其用途 | |
| CN101445559B (zh) | 三聚体可溶抗体与其产生及使用的方法 | |
| JPWO2022224997A5 (https=) | ||
| JPWO2021241616A5 (https=) | ||
| JP2018502050A5 (https=) | ||
| CN103012589B (zh) | 人源抗人血管内皮细胞生长因子抗体及其应用 | |
| CN113195530B (zh) | 抗体融合蛋白、制备方法及其应用 | |
| US20240182582A1 (en) | Materials and methods for immune effector cells redirection | |
| JP2025512865A5 (https=) | ||
| US20220306760A1 (en) | Igm glycovariants | |
| JP2021507698A5 (https=) | ||
| JP2005528914A5 (https=) | ||
| JP2020515277A5 (https=) | ||
| KR20150064204A (ko) | 인간 유래 항-인간 표피 생장인자 수용체 항체 및 그의 코딩 유전자와 용도 | |
| TW201134489A (en) | Basigin binding proteins | |
| US20220112276A1 (en) | Biosynthetic materials and methods for multidirectional biotransportation | |
| JP2024516098A (ja) | Ｂｃｍａを標的とする多重特異性抗体 | |
| JP2022079486A5 (https=) | ||
| JP2023182689A5 (https=) | ||
| JPWO2022102768A5 (https=) | ||
| WO2019062831A1 (zh) | Il-5抗体、其抗原结合片段及医药用途 | |
| JP2024542235A5 (https=) | ||
| CN115991782A (zh) | 抗间皮素纳米抗体及其用途 |